Company: PRME
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001628280-25-018704
Chunk: 51

Company: Prime Medicine, Inc.
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 51
---
 payments or benefits will be reduced if such reduction would result in a higher net after-tax benefit to him.

<div align='center'>32</div>

#### Equity Compensation Plan Information
The following table provides information as of December 31, 2024 with respect to the shares of our common stock that may be issued under our existing equity compensation plans:

| Plan category                                              
 Equity compensation plans approved by security holders     |     | Number of securities to be issued upon exercise of outstanding options, warrants and rights |            |     | Weighted-average exercise price of outstanding options, warrants and rights |      |     | Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in first column) |            |
|:-----------------------------------------------------------|:----|:--------------------------------------------------------------------------------------------|-----------:|:----|:----------------------------------------------------------------------------|-----:|:----|:----------------------------------------------------------------------------------------------------------------------------------------------|-----------:|
| Stock options (1) (2)                                      |     |                                                                                             | 12,472,421 |     | $                                                                           | 8.93 |     |                                                                                                                                               |  9,049,689 |
| 2022 Employee Stock Purchase Plan (3) (4)                  |     |                                                                                             |          — |     |                                                                             |    — |     |                                                                                                                                               |  1,753,191 |
| Equity compensation plans not approved by security holders |     |                                                                                             |          — |     |                                                                             |    — |     |                                                                                                                                               |          — |
| Total                                                      |     |                                                                                             | 12,472,421 |     | $                                                                           | 8.93 |     |                                                                                                                                               | 10,802,880 |

1. Number of shares to be issued pursuant to outstanding options includes 11,410,691 stock options with a weighted-average exercise price of $9.08 outstanding under our 2019 Plan and our 2022 Plan, and 1,061,730 performance-based stock options with a weighted-average exercise price of $7.31 under our 2019 Plan.

2. Shares of our common stock available for future issuance as of December 31, 2024 pursuant to the 2022 Plan excludes the 6,558,042 shares that were added to the plan as a result of the automatic annual increase on January 1, 2025. The 2022 Plan provides that the number of shares reserved and available for issuance under the 2022 Plan will automatically increase on January 1, 2023 and each January